Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13287-020-01804-6 http://scihub22266oqcxt.onion/10.1186/s13287-020-01804-6 32698898!7373844!32698898     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Stem+Cell+Res+Ther 2020 ; 11 (1): 305 Nephropedia Template TP {{tp|p=32698898|t=2020. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 |pdf=|usr=}}{{32698898}} gab.com Text Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 JO: Stem Cell Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=32698898 #FOAvip Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic. Twit Text FOAVip Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 ????Stem Cell Res Ther http://www.kidney.de/pget.php?&tw=1&pmid=32698898 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32698898 #FOAvip English Wikipedia <ref>{{Cite pmid|32698898}}</ref> Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 #MMPMID32698898 Xiao K; Hou F; Huang X; Li B; Qian ZR; Xie L Stem Cell Res Ther 2020[Jul]; 11 (1): 305 PMID32698898show ga Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic. |Betacoronavirus[MESH] |COVID-19[MESH] |Cell- and Tissue-Based Therapy/*methods[MESH] |Coronavirus Infections/*therapy[MESH] |Cytokine Release Syndrome/therapy[MESH] |Humans[MESH] |Mesenchymal Stem Cell Transplantation/*methods[MESH] |Mesenchymal Stem Cells[MESH] |Pandemics[MESH] |Pneumonia, Viral/*therapy[MESH] |Respiratory Distress Syndrome/*therapy[MESH]Mesenchymal stem cells: current clinical progress in ARDS and COVID-19(epmc).pdf DeepDyve Pubget Overpricing